Showing 1,241 - 1,260 results of 1,661 for search '"Biomedical sciences"', query time: 0.06s Refine Results
  1. 1241
  2. 1242
  3. 1243
  4. 1244
  5. 1245
  6. 1246
  7. 1247
  8. 1248
  9. 1249
  10. 1250
  11. 1251
  12. 1252
  13. 1253
  14. 1254

    Dynamic Complement Protein Changes in Aqueous Humor and Plasma of Patients With Retinal Vein Occlusion During Ranibizumab Treatment by Guo T, Zhao Y, Liang S, Wang J, Liu H, Zhou Y, Xu H, Chen Z

    Published 2025-01-01
    “…Tingting Guo,1,2,* Yanying Zhao,2,3,* Shengnan Liang,2,3 Jie Wang,2 Hengwei Liu,2 Yufan Zhou,2 Heping Xu,3– 5 Zhongping Chen1– 3,6 1Aier Eye Hospital, Jinan University, Guangzhou, People’s Republic of China; 2Changsha Aier Eye Hospital, Changsha, People’s Republic of China; 3Aier Academy of Ophthalmology, Central South University, Changsha, People’s Republic of China; 4Aier Institute of Optometry and Vision Science, Aier Eye Hospital Group, Changsha, People’s Republic of China; 5The Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, Belfast, UK; 6School of Stomatology and Ophthalmology, Xianning Medical College, Xianning, People’s Republic of China*These authors contributed equally to this workCorrespondence: Zhongping Chen; Heping Xu, Email chenzhongping@csu.edu.cn; heping.xu@qub.ac.ukPurpose: To assess dynamic changes of complement protein in aqueous humor (AH) and plasma of retinal vein occlusion (RVO) patients during ranibizumab treatment, and to explore the differential expression of complement proteins in branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO).Patients and Methods: This prospective, consecutive case series study collected AH and plasma samples from 27 RVO patients at baseline, 1 and 2 months after ranibizumab treatment, including 19 BRVO and 8 CRVO patients. …”
    Get full text
    Article
  15. 1255
  16. 1256
  17. 1257
  18. 1258
  19. 1259
  20. 1260